CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 247 enrolled
Drug / intervention
AZD7268 +3 moredrug
Likely dose
AZD7268 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01020799
NCT01020799Phase 2Completed
CompareCT.gov

A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder

AstraZeneca·interventional·Posted Nov 26, 2009·Updated Apr 17, 2012

In Brief

A Phase 2 clinical trial evaluating AZD7268, Escitalopram, and 2 other interventions for Major Depressive Disorder. Completed, enrolled 247 participants across 17 sites.

Detailed Summary

The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.6 years ago

Interventions

AZD7268drug

15 mg, oral, twice daily (BID)

Escitalopramdrug

20 mg, oral, once daily (QD)

Placebo capsulesdrug

Placebo capsules to match AZD7268

Placebo tabletsdrug

Placebo tablets to match encapsulated escitalopram